Exodus Point Capital Management, LP Rhythm Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$15.81 - $27.8 $2.16 Million - $3.8 Million	136,762 Added 872.15%	152,443 $3.5 Million
Q2 2023 Aug 10, 2023	SELL	$16.32 - $21.15 $619,784 - $803,213	-37,977 Reduced 70.78%	15,681 $259,000
Q1 2023 May 11, 2023	BUY	$16.88 - $34.24 $905,747 - $1.84 Million	53,658 New	53,658 $957,000
Q1 2022 May 13, 2022	SELL	$6.13 - $12.24 $94,861 - $189,414	-15,475 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$8.62 - $13.9 $33,393 - $53,848	3,874 Added 33.39%	15,475 $154,000
Q3 2021 Nov 15, 2021	SELL	$11.68 - $20.72 $39,046 - $69,266	-3,343 Reduced 22.37%	11,601 $152,000
Q2 2021 Aug 16, 2021	BUY	$18.52 - $22.55 $276,762 - $336,987	14,944 New	14,944 $293,000
Q3 2020 Nov 16, 2020	SELL	$18.13 - $30.61 $244,446 - $412,714	-13,483 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$14.41 - $25.35 $194,290 - $341,794	13,483 New	13,483 $301,000
Q2 2019 Aug 14, 2019	SELL	$21.11 - $28.48 $413,671 - $558,094	-19,596 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$24.76 - $31.66 $485,196 - $620,409	19,596 New	19,596 $537,000

191

67.3M

834K

78.6K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.13B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.